R&D channel feed – Endpoints News

R&D channel feed

JP Gabriel watched from the bleachers as the pandemic raged. Now head of supply chain at Ocugen, he's ready to bat

5 years ago

Syndax looks to rebound from stinging late-stage failure, uncorking early data for next cancer drug up

5 years ago

FDA slaps a hold on KalVista's PhII study of an HAE drug, raising a red flag on preclinical results

5 years ago

FDA lays the hammer on Emergent's Baltimore plant after J&J debacle, halting all production in unusual move

5 years ago

New Kaiser analysis shows how limiting price negotiations to targeted drugs may better focus upcoming legislation

5 years ago

Ovid cuts its losses on controversial Angelman syndrome drug, making its crushing development halt permanent

5 years ago

FDA slaps a hold on Moffitt’s next-gen CAR-T as regulators demand another delay on clinical work — shares crater

5 years ago

Looking to cement its lead in packed MS market, Roche's Ocrevus uncorks new data in early-stage patients

5 years ago

Avrobio is using 'pods' to create gene therapies, and it believes the approach could change the game altogether

5 years ago

FDA blasts Colombian drug manufacturer in warning letter for not properly addressing API flaws

5 years ago

Alchemab bags fresh round of investors for target-agnostic antibody development for Huntington's, Covid-19

5 years ago

Activist investor grabs a multibillion-pound stake in GlaxoSmithKline, triggering buzz about a looming showdown at the listless giant

5 years ago

Merck scraps their $425M Covid-19 drug in latest pandemic setback

5 years ago

Covid-19 roundup: J&J shot remains on hold after CDC panel vote

5 years ago

GlaxoSmithKline scraps two key mid-stage trials for their ICOS drug in the latest setback for the field

5 years ago

'Learned a lot last year': After Covid-19 success, Moderna's Stéphane Bancel plans to give rest of pipeline a big push

5 years ago

Moderna says Covid-19 boosters stand a fighting chance against new variants

5 years ago

Tumor-treating electric fields show early promise in NSCLC — boosting both Novocure and its Chinese biotech partner

5 years ago

Bain doubles down on Tony Coles’ quest to get a late-stage Parkinson’s drug through to market

5 years ago

Arcellx raises mega-round to put controllable CAR-T into the clinic

5 years ago

OrbiMed-backed Theseus debuts with $100M round in heroic quest for 'pan-variant' kinase inhibitors

5 years ago

Sage touts first win in $3B Biogen pact, but safety profile, doubts over data cloud road ahead

5 years ago

AACR21: Eli Lilly blazes new trail for RET inhibitor, ginning up a response in 9 solid tumor types in early data

5 years ago

AACR21: iTeos busts out early human data for anti-TIGIT antibody. Is it enough to match up with Roche, Merck?

5 years ago

First page Previous page 172 173 174175176 177 178 Next page Last page